CONTACT
+91 80 2808 2808
info@biocon.com

Press Releases

Biocon  /  News – Posts  /  Press Releases

Biocon Limited Concludes a Rs 4,500 Crore (USD 523 million ) Equity Fundraise through a Qualified Institutions Placement (QIP)

  • Posted by: BIOCON

Biocon Foundation in Partnership with NCBS and BeST Cluster Launches BioWISE Program – to Empower Women in STEM

  • Posted by: BIOCON

Biocon Limited gets approval for diabetes drug Liraglutide in India

  • Posted by: BIOCON

Biocon Q4FY25 Revenue at Rs 4,454 Cr, Up 15%** EBITDA at Rs 1,115 Cr; Up 16%; Net Profit at Rs 344 Cr, Up 153%

  • Posted by: BIOCON

Biocon Biologics Secures Strong Market Access Coverage for Yesintek™ in the United States Covering 100+ Million Lives

  • Posted by: BIOCON

Biocon Biologics Secures Market Entry Date for Yesafili™, an Interchangeable Biosimilar to Eylea®, in the U.S.

  • Posted by: BIOCON

Biocon Pharma Limited Receives U.S. FDA Approval for ANDA of Everolimus Tablets

  • Posted by: BIOCON

Biocon Biologics Announces U.S. FDA Approval for Jobevne™, Biosimilar Bevacizumab, Expanding Its Oncology Portfolio

  • Posted by: BIOCON

Biocon Biologics Announces Positive Results from Phase 3 Study of Yesintek™ Biosimilar to Ustekinumab for Chronic Plaque Psoriasis

  • Posted by: BIOCON

Biocon Biologics and Civica, Inc. Collaborate to Expand Insulin Aspart Access in the United States

  • Posted by: BIOCON
Share
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>